Drl Impex Profile
Key Indicators
- Authorised Capital ₹ 77.00 Cr
as on 29-06-2024
- Paid Up Capital ₹ 76.00 Cr
as on 29-06-2024
- Company Age 38 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -10.71%
(FY 2023)
- Ebitda -10.71%
(FY 2023)
- Net Worth -3.19%
(FY 2023)
- Total Assets -0.57%
(FY 2023)
About Drl Impex
The Corporate was formerly known as Drl Pharmaceuticals Ltd. The Company is engaged in the Chemicals And Resources Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 77.00 Cr and a paid-up capital of Rs 76.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Drl Impex Limited India are Narayana Vuyyuru as CEO and Richa Periwal as Cfo. Amit Parekh, Namrata, and Venkatanarasimham Mannam serve as directors at the Company.
- CIN/LLPIN
U65990TG1986PLC006695
- Company No.
006695
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Aug 1986
- Date of AGM
20 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Drl Impex?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayana Vuyyuru  | CEO | 01-Feb-2017 | Current |
| Richa Periwal | CFO | 28-Mar-2023 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Amit Parekh | Director | 31-Jan-2023 | Current |
| Namrata | Director | 30-Oct-2019 | Current |
| Venkatanarasimham Mannam | Director | 25-Sep-2014 | Current |
Financial Performance and Corporate Structure Insights of Drl Impex.
Drl Impex Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 10.71% decrease in profit. The company's net worth dipped by a decrease of 3.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Drl Impex?
In 2023, Drl Impex had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aurigene Pharmaceutical Services Limited
Active
5 years 22 days Venkatanarasimham Mannam is a mutual person
Dr.Reddy's Research Foundation
Active 38 years 7 months Amit Parekh and Venkatanarasimham Mannam are mutual person
Idea2enterprises (India) Private Limited
Active 24 years 4 months Venkatanarasimham Mannam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Drl Impex?
Unlock and access historical data on people associated with Drl Impex, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Aug 02, 2016, Drl Impex has raised a total of ₹ 10 Cr, with the most recent deal valued at ₹ 10 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
